Introduction: Subcutaneous fat wasting in HIV therapy is primarily associated with the use of stavudine (d4T) and zidovudine (AZT). We hypothesized that C-reactive protein (CRP) might have an additive effect on nucleoside reverse transcriptase inhibitor (NRTI)-mediated peripheral fat loss. Methods: 3T3-F442A cells were exposed to AZT (6 µM), d4T (3 µM) and/or CRP (0.5 µg/ml) during differentiation. Differentiation was assessed by real-time PCR measurement of peroxisome proliferator-activated receptor (PPAR)γ and CCAAT/enhancer-binding protein (C/EBP)α, by quantification of triglyceride accumulation and by determination of adiponectin expression and secretion. In addition, parameters of lipid accumulation, lipolysis, cell viability and apoptosis were examined. Results: When preadipocytes were induced to differentiate in the presence of only AZT, d4T or CRP, only AZT significantly impaired adipogenic differentiation. When combined, d4T+CRP also led to reduced triacylglycerol accumulation, an effect not explained by CRP-induced apoptosis or cell death, but instead confirmed by reduced PPARγ and C/EBPα expression and decreased expression of factors involved in lipogenesis, such as fatty acid synthase and acetyl-coenzyme A carboxylase. We observed further reduction in adiponectin expression and secretion when adipocytes were differentiated in the presence of AZT or d4T together with CRP. Addition of rosiglitazone (1 µM) had no effect on reduced adipogenesis, but partially rescued the effects of d4T and d4T+CRP on adiponectin production. Conclusions: We conclude that CRP at levels circulating in patients with HIV infection might promote the antiadipogenic potential of d4T, a cooperative effect that could account for the in vivo observed variability in the development of lipoatrophy.
Highly active antiretroviral therapy (HAART) has been associated with pathological alterations, such as dyslipidaemia, impaired glucose metabolism and fat redistribution, which are all summarized under the term 'lipodystrophy syndrome' or HIV-related lipodystrophy (HIV-LD) [1] . Interestingly, both HIV-LD as well as type-2 diabetes have been in one way or another related to chronic inflammation [1, 2] , which experimental and clinical data suggested to be a key player in the development of these metabolic alterations [1, [3] [4] [5] . Typical characteristics of chronic inflammation are disturbed cytokine homeostasis, increased acute phase reactants and stimulated inflammatory pathways [1, 5] . One of the paramount markers of inflammation is C-reactive protein (CRP), synthesized primarily in the liver [6] and, as recently discovered, in adipocytes in response to inflammatory stimuli [7] . Circulating levels of CRP (approximately ≤5 mg/l) have been described in patients with HIV infection [8] , type-2 diabetes mellitus [9, 10] or metabolic syndromes [11, 12] . A number of studies have documented hypoadiponectinaemia and impaired insulin sensitivity in the setting of high CRP circulating levels [13, 14] . In vivo reciprocal association of adiponectin and CRP levels in both human plasma and adipose tissue has been reported [13] , and such correlation has been confirmed in vitro, where CRP has been shown to exert a negative effect on adipocyte expression and secretion of adiponectin [15] . However, thus far, it has not been determined whether increased CRP levels might contribute to nucleoside reverse transcriptase inhibitor (NRTI)-associated antiadipogenic effects. Many inflammatory cytokines, such as interleukin (IL)-1, IL-6 and tumour necrosis factor (TNF)-α, produced by adipocytes and monocytes have been shown to inhibit in vitro adipogenesis and have been hypothesized to play a role in the development of lipoatrophy as part of HIV-LD [16] . In addition, in vitro studies suggested that the peroxisome proliferator-activated Introduction receptor (PPAR)γ agonist, rosiglitazone (Rosi), is able to reverse the antiadipogenic effects of some proinflammatory cytokines (such as IL-6 [17] ) and HIV drugs (such as indinavir [18] ). This and other insulinsensitizing drugs from the group of thiazolidinediones have been shown to increase the expression and circulating levels of the insulin-sensitizing adipokine adiponectin [19] .
Currently, the development of lipoatrophy is strongly associated with the use of NRTI therapy, particularly stavudine (d4T) [20] [21] [22] , which is an effect that is supposed to be influenced by individual host factors [20] . We hypothesized that inflammatory mechanisms contribute to the antiadipogenic effect of d4T observed in patients developing lipoatrophy. We aimed to study the combined effect of CRP and NRTI treatment on adipogenesis, lipid metabolism and cell viability in a well established in vitro model.
Methods

Cell culture
3T3-F442A preadipocytes were kindly provided by Dr Jacqueline Capeau (INSERM, Paris, France) and cultured as previously described [23] . Preadipocytes were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 5% newborn calf serum (NCS) with 100 U/100 µg/ml penicillin/streptomycin (preadipocyte medium). Subconfluent preadipocytes were cultured for 2 days in preadipocyte medium supplemented with 5% NCS and 5% fetal calf serum (FCS). For differentiation, preadipocyte medium containing 10% FCS, 4 µg/ml panthotenic acid and 8 µg/ml biotin and supplemented with 1 µM insulin (Sigma-Aldrich, Saint Louis, MO, USA) was added to cells 2 days after confluence (designated day 0) and incubation continued until day 9. Zidovudine (AZT) and d4T (SigmaAldrich) were dissolved in dimethyl sulfoxide (DMSO). The concentrations used were the approximate therapeutic maximum concentration (C max ) levels for AZT (6 µM) and d4T (3 µM) as discussed previously [23] . CRP was from Calbiochem (Darmstadt, Germany) and stored in liquid (140 mM NaCl, 10 mM Tris, 2 mM CaCl 2 , 0.1% NaN 3 and pH 8.0). Rosi (Cayman Europe, Hamburg, Germany) was dissolved in DMSO and used in a concentration of 1 µM as described previously in adipocyte in vitro experiments [17, 18] . The highest concentration of the solvent used in the incubation experiments (DMSO 0.1%) did not affect cellular viability and preadipocyte differentiation. The extent of preadipocyte differentiation was assessed by Oil red O staining and microscopically for the acquisition of a spherical shape and triacylglyceride droplet accumulation. Cell numbers and viability were determined microscopically using trypan blue staining.
RNA preparation and real-time quantitative PCR
Total RNA extraction was conducted using the RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany). Complementary (cDNA) was reversed transcribed from total RNA in 20 µl using random nonamers and oligo dT primers and the Omniscript RT Kit (Qiagen). Primer design was done using Primer3 software [24] . Realtime quantitative PCR analyses for the genes encoding PPARγ, CCAAT/enhancer-binding protein (C/EBP)α, adiponectin, adipocyte lipid-binding protein 2 (aP2), fatty acid synthase (FAS) and acetyl-coenzyme A carboxylase (ACC) were done in a final volume of 25 µl using QuantiTect SYBR Green PCR Kit (Qiagen). The primers used were transferrin receptor (housekeeping gene) forward primer 5′-TCCGCTCGTGGAGACTACTT-3′, reverse primer 5′-ACATAGGGCGACAGGAAGTG-3′, 18S (housekeeping gene) forward primer 5′-AGTT GCTGCAGTTAAAAAGC-3′, reverse primer 5′-ACTC AGCTAAGAGCATCGAG-3′, PPARγ forward primer 5′-CGAGTCTGTGGGGATAAAGC-3′ reverse primer 5′-GGATCCGGCAGTTAAGATCA-3′, C/EBPα forward primer 5′-TGGACAAGAACAGCAACGAG-3′, reverse primer 5′-TCACTGGTCAACTCCAGCAC-3′ adiponectin forward primer 5′-GGAACTTGTG CAGGTTGGAT-3′, reverse primer 5′-CCAAGAAGA CCTGCATCTCC-3′, ACC forward primer 5′-CGA TTCATAATTGGGTCTGT-3′, reverse primer 5′-TCT TTCTGTCTCGACCTTGT-3′, FAS forward primer 5′-ATGATGACAGGAGATGGAAG-3′, reverse primer 5′-AGTGAGGCTGGGTTGATAC-3′, and aP2 forward primer 5′-GGAAGGTGAAGAGCATCATA-3′ and reverse primer 5′-GAAGTCACGCCTTTCATAAC-3′. Amplifications were completed in purposely designed optical 96-well plates using a spectrofluorometric thermal cycler (iCycler; BioRad, Munich, Germany). The genes of interest and housekeeping gene products were amplified separately using equal cycling conditions. An initial cycle at 95°C for 15 min incubation was performed in order to activate the HotStarTaq DNA Polymerase (Qiagen), followed by 42 cycles each containing one step at 94°C (15 s) for denaturation, one step at 55°C (30 s) for annealing and one step at 72°C (30 s) for extension. PCR products were analysed by melting curve analysis and on ethidium-bromide-stained agarose gel to ensure that a single amplicon of the estimated length was obtained. Serial dilutions (1, 1/5 and 1/25) of reverse transcribed RNA were amplified and a standard curve was constructed by plotting cycle threshold values as a function of starting cDNA, the slope of which was used for the calculation of PCR efficiency using the iCycler software. The relative quantification for the genes of interest was calculated by dividing the standard curve value of the particular gene A by that of the calibrator gene B (transferrin receptor or 18S) in treated and control cells. The choice of transferrin receptor and 18S as housekeeping genes was because they have been shown to be superior to a number of other commonly used housekeeping genes in adipocyte and preadipocyte analysis of differentiation [25] . The expression of some standard housekeeping genes, such as actin, has been shown to be highly influenced during early differentiation [26] . The effect of different drug incubations were calculated by comparing mean values obtained from three independent experiments. In each of the three experiments, RNA from three independent culture wells was isolated and pooled. The pooled RNA was reverse transcribed and cDNA obtained by three separate reactions. This cDNA was again pooled and measured in a real-time PCR in triplicate. The triplicate real-time PCR results of three independent experiments were used for statistical evaluation. These were compared with the mean value of the control cells processed in an identical manner.
Adipocyte staining with Oil red O
For Oil red O (Sigma-Aldrich) staining, adherent cells were fixed in 10% formalin, washed and stained with a 0.21% (w/v) Oil red O solution (60% isopropanol and 40% water). At this level, Oil red O staining was studied by conventional fluorescence microscopy. For objective quantification of triacylglyceride content, cells were dried, and Oil red O extracted with 100% isopropanol and photometrically measured at 495 nm.
Lipolysis assays
Lipolysis was assessed as glycerol release into culture medium as explained previously [27] . Briefly, 3T3-F442A preadipocytes were differentiated in 12-well plates in the presence or absence of therapeutic C max concentrations of AZT (6 µM), d4T (3 µM) and CRP (5 µg/ml) alone or in combination of AZT or d4T with CRP for 8 days. At this time point, the medium was replaced with DMEM/F-12 (phenol red free) 500 µl/ well supplemented with 2% bovine serum albumin and the indicated treatment for 24 h. Glycerol release was assessed in triplicates using Free Glycerol Reagent (Sigma-Aldrich) according to the manufacturer's instructions. Results were presented as µg of glycerol per 10 6 cells per h.
Cell viability and apoptosis
The proportion of dead cells from both adherent and floating cells was measured microscopically using trypan blue exclusion. Every time the cell culture medium was changed (three times in total), the proportion of dead cells was counted and used to calculate the cumulative percentage of dead cells for the entire differentiation period. Analysis of apoptosis was performed using propidium iodide staining and flow cytometry according to the method developed by Riccardi and Nicoletti [28] , which has been used by others for in vitro experiments using the 3T3-F442A cell line [29] .
ELISAs
The Quantikine Mouse Adiponectin Immunoassay ELISA (R&D Systems, Wiesbaden-Nordenstadt, Germany), designed to measure full-length mouse adiponectin levels in cell culture supernatants, was used according to the manufacturer's instructions. Measurements of adiponectin were a result of 2 days secretion of 3T3-F442A adipocytes in 24-well plates.
Statistical analyses
The statistical evaluation for comparisons of more than two groups was performed by ANOVA with Bonferroni's post hoc analysis. The level of significance was set at P<0.05. All data are presented as mean ±sem. All calculations were performed using SPSS 15.0 (Chicago, IL, USA) for Windows.
Results
Effect of CRP alone and combined with NRTI on differentiation-dependent triacylglyceride accumulation
Extending our earlier observations [23, 30] , the 3T3-F442A cell line was induced to differentiate in the presence or absence of therapeutic C max concentrations of AZT (6 µM), d4T (3 µM), CRP (5 µg/ml) and Rosi (1 µM) or combination of AZT or d4T with either CRP or CRP+Rosi added on day 0 until day 9 (from differentiation). The CRP concentration was chosen because similar levels have been found in the serum of HIV-infected patients [31] . From the single substance incubations (AZT, d4T and CRP), only adipocytes exposed to AZT presented significant decrease in the amount of triacylglycerol droplets ( Figure 1A ) compared with vehicle-treated cells at day 9, similar to earlier observations [29, 30, 32] and confirmed by objective quantification of Oil red O staining ( Figure 1B) . By contrast, 3T3-F442A adipocytes exposed to vehicle proceeded unaffected through the differentiation process and acquired a typical mature phenotype with round shape and multiple lipid droplets. Under these experimental conditions, cultures exposed to CRP or d4T did not seem to differ from control ( Figure 1A and 1B), suggesting that CRP alone at a concentration corresponding to the circulating levels in HIV-positive patients is not sufficient to disturb the differentiationdependent triacylglyceride accumulation and acquisition of a mature phenotype in adipocytes; however, when adipocytes were exposed to d4T+CRP, a noticeable decrease in the amount of triacylglycerol droplets compared with vehicle-treated cells was evident at day 9 as compared with controls ( Figure 1A ). This effect was statistically significant when quantified by Oil red 
Effect of CRP alone and combined with NRTI on adipogenic marker expression
To further analyse the effect of CRP on adipogenesis, 3T3-F442A cells were induced to differentiate in the presence or absence of therapeutic C max concentrations of AZT (6 µM), d4T (3 µM), CRP (5 µg/ml) and Rosi (1 µM) or a combination of AZT or d4T with either CRP or CRP+Rosi added on day 0 until day 9 (from differentiation). At days 4 and 6 of the differentiation protocol, messenger RNA (mRNA) was isolated, reverse transcribed and real-time PCR analysis was performed to assess expression levels of two transcription factors involved in a cascade during preadipocyte differentiation. Analysis of the expression levels of the adipogenic transcription factors PPARγ and C/EBPα at day 4 and 6, respectively, which are the time points of the peak expression of these factors during adipogenesis, demonstrated reduction in AZT-treated cultures when compared with those of vehicle-treated cells (Figure 1C and 1D ). However, in accordance with the effect on triacylglyceride accumulation, no significant difference was observed in the CRP-and d4T-treated cultures confirming once more the inability of these substances to disturb adipocyte differentiation at concentrations used here. By contrast, combination of d4T+CRP led to significant reduction in PPARγ and C/EBPα expression as compared with vehicle-treated cultures or to d4T or CRP single-treated cultures ( Figure 1C and 1D) . These results confirmed the combined antiadipogenic effect of these substances suggested by the disturbed triacylglyceride accumulation ( Figure 1A and 1B). No combined effect was observed in the AZT+CRP coincubations. Analysis of expression levels of the adipogenic transcription factors PPARγ and C/EBPα at days 4 and 6 failed to substantiate positive effects of Rosi on the antiadipogenic properties of d4T+CRP combinations and confirmed the lack of effect in AZT and AZT+CRP cultures ( Figure 1C and 1D) . When considered together, these results indicate a combinatory antiadipogenic effect of d4T+CRP, which was not compensated by the addition of Rosi.
Coincubation with CRP+d4T affects the expression of adipogenic markers involved in lipid accumulation
Considering the effects of AZT, AZT+CRP and d4T+CRP incubations on the transcription factor expression important for differentiation and triacylglyceride accumulation, we analysed whether this was accompanied by impaired expression of adipogenic markers involved in lipid accumulation. To this end, 3T3-F442A cells were induced to differentiate in the presence or absence of 6 µM AZT, 3 µM d4T and 5 µg/ ml CRP or combination of AZT or d4T with CRP added on day 0 until day 6 (from start of differentiation) when real-time PCR analysis were performed to assess expression levels of FAS, ACC and aP2. This time point has been used by others in a similar in vitro experiment [29] . As depicted in Figure 2 and consistent with our results obtained by the Oil red O staining and PPARγ and C/EBPα expression, AZT, AZT+CRP and d4T+CRP induced a significant decrease in expression of FAS, ACC and aP2 at day 6.
CRP alone or in combination with NRTI has no effect on lipolysis
As AZT, AZT+CRP and d4T+CRP incubations decreased the differentiation-dependent lipid accumulation, we wished to examine the effect of these combinations on lipolysis (glycerol release). To this end, 3T3-F442A were differentiated under the standard protocol in the presence or absence of therapeutic C max concentrations of AZT (6 µM), d4T (3 µM) or CRP (5 µg/ ml) alone or in combination of AZT or d4T with CRP for 8 days. At this time point, the medium was replaced and glycerol release measured during the next 24 h. The glycerol release was expressed as µg per 10 6 cells per h. We were unable to detect substantial alterations in the level of basic lipolysis as a result of single AZT, d4T or CRP incubation. Furthermore, the combination of AZT or d4T with CRP had no additional effect on lipolysis under our experimental conditions ( Figure 3A) .
CRP alone and in combination with d4T does not affect cell viability
3T3-F442A cells were induced to differentiate in the presence or absence of 6 µM AZT, 3 µM d4T and 5 µg/ ml CRP or combination of AZT or d4T with CRP added on day 0 until day 9 (from start of differentiation). Cumulative cell death of adherent and floating cells for the entire differentiation time period was calculated. In cultures of 3T3-F442A cells differentiating in the presence of therapeutic C max concentrations of AZT and AZT+CRP, there was a moderate but significant cumulative increase in cell death as compared with control ( Figure 3B ). Flow cytometry analysis of apoptosis [28] demonstrated an increase in the level of apoptotic cells in AZT-containing incubations ( Figure  3C and 3D) corresponding to the pattern of cell death ( Figure 3B) . Importantly, however, neither cell death nor apoptosis levels were influenced by the addition of CRP to the NRTI treatment.
CRP deteriorates the effect of AZT and d4T on adiponectin production
Given that an earlier study suggested CRP to have a negative effect on adipocyte adiponectin production [15] , we decided to assess the effect of NRTI+CRP coincubations on the production of adiponectin. 3T3-F442A cells were induced to differentiate in the presence of AZT (6 µM) alone, d4T (3 µM) alone, each together with CRP (5 µg/ml) or the above combinations together with Rosi (1 µM) added on day 0 until day 9 (from start of differentiation). At day 9 of the differentiation protocol, mRNA was isolated, reverse transcribed and real-time PCR analysis performed to assess adiponectin expression. At the same time point, supernatant containing 2 days secretion from day 7 to day 9 was taken for ELISA measurement of adiponectin secretion. Overall, analysis of adiponectin expression and secretion led to very similar patterns when different culture conditions were compared. Incubation with only AZT or d4T demonstrated a significant reduction by about 60% in adiponectin secretion and expression, as compared with results of vehicle-treated cells, similar to earlier observations [30, 33, 34] . CRP alone lead to a reduction in adiponectin expression by approximately 40%, but this difference did not reach statistical significance. A previous study demonstrated that 24 h CRP incubation at concentrations of 50 µM, which is 10× higher than used in our experiments, exerted an inhibitory effect on adiponectin production [15] ; however, the choice of CRP concentration in our experiments was dictated by the circulating serum concentration in HIV-infected patients [31] and also by the requirement for a long period (9 days) of incubation during which the higher concentrations (25 and 50 µg/ml) were toxic to the cell line (data not shown). The coincubations of AZT+CRP and d4T+CRP led to a slight additional impairment of the already significantly affected adiponectin expression, as the differences became highly significant under these conditions ( Figure 4A ). The addition of Rosi was able to partially rescue the negative effect of d4T and d4T+CRP cultures and the highly significant reduction 
Discussion
Fat redistribution remains a major concern in HIV therapy and is characterized also by pathological alterations such as dyslipidaemia and impaired glucose metabolism [1] . The development of peripheral fat wasting has been mostly related to the use of NRTIs and in particular d4T and AZT [21, 22] . Adipocytes appear to be not only a target of HIV therapy, but might themselves contribute to the metabolic part of HIV-LD. Fat tissue affects whole body insulin sensitivity through the release of adiponectin, which is able to increase insulin sensitivity, and through IL-6 and TNF-α, both of which are associated with insulin resistance [1] . Adipose tissue homeostasis is maintained through a highly controlled balance of cell proliferation, differentiation and cell death. Recently, it has been demostrated that fat mass in adults is mainly determined by the adipocyte number and that this number is maintained constant by an approximately 10% annual adipocyte turnover independent of the adult age and body mass index [35] . Interestingly, impaired expression of adipogenic markers in subcutaneous abdominal adipose tissue from HIV type-1-infected patients with peripheral lipoatrophy has been documented [36] and impaired differentiation has been hypothesized to be one of the reasons for fat tissue atrophy. Factors such as impaired lipogenesis or enhanced lipolysis and adipocyte cell death might also influence the final lipoatrophic outcome of fat depots.
Evidence from clinical trials, observational cohort studies and pathological studies demonstrated association of lipoatrophy with the use of d4T, and to a lesser extent AZT [20] [21] [22] . As the risk of NRTI-associated lipoatrophy has been suggested to be significantly modulated by host factors [20] , we hypothesized that additional factors could potentially act synergistically with NRTI-mediated antiadipogenic effects. HIV-LD has been associated with increased levels of several proinflammatory cytokines, most of which are produced by dysfunctional adipocytes themselves [1] . Indeed, several insulin resistance inducing proinflammatory cytokines, such as TNF-α, IL-1 and IL-6 have been shown to reduce adiponectin production and to inhibit adipocyte differentiation [17, [37] [38] [39] . In this study, we addressed the question of whether CRP in combination with NRTIs might play a role in the firstline antiadipogenic effects, thereby switching on the vicious cycle of adipocyte dysfunction. HAART has been independently associated with an increase in the circulating levels of this marker [8] . In addition, dysfunctional adipocytes and adipose macrophages produce more IL-1 and IL-6 [33, 40] , which, as shown in vitro in primary cultures of adult human hepatocytes [6] , induces further hepatic CRP synthesis and thus might close a vicious cycle between liver and adipose tissue in the settings of NRTI treatment and inflammation. Increased CRP levels release has also been documented in response to inflammatory cytokines, such as IL-1 and IL-6 by human adipocytes, which means that this acute phase reactant would also potentially act through the paracrine and autocrine mechanisms [7] . In the current study, we therefore examined the in vitro effect of CRP alone and in combination with d4T and AZT on adipogenesis, lipid metabolism, cell viability, adiponectin gene expression and secretion in differentiating 3T3-F442A adipocytes. We demonstrate that the presence of CRP alone at a concentration corresponding to that observed in the serum of HIV-positive patients [31] , is ineffective to disturb the process of adipocyte differentiation and adiponectin production. The unaffected expression of transcription factors, such as PPARγ and C/EBPα, which coordinate the expression of most genes induced in adipogenesis [41] , was accompanied by normal expression of adipogenic markers involved in lipid accumulation. However, the combination of d4T+CRP demonstrated relevant antiadipogenic properties that were not observed, when the two substances were applied separately. We wish to emphasize that in accordance with our hypothesis and our aim to study the effect of CRP on NRTIassociated effects on adipocytes, we anticipated that it might be advantageous to avoid exceeding therapeutically observed C max concentrations of approximately 2.5 µM as discussed in reference [23] , in order to be able to quantify additive or synergistic effects. Another study by Caron et al. [29] demonstrated that 10 µM of d4T, corresponding to 4× higher C max concentrations as measured in humans after therapeutic dosing [42] , has the potency to inhibit 3T3-F442A adipocyte differentiation and to induce a several fold increase in cell death. Using human primary adipocytes, the same group demonstrated that 10 µM d4T decreased the cell survival rate by 28-31% during only 48 h of incubation [33] . Drug concentration differences might explain why we did not see a significant effect of d4T on adipogenesis in our study, but instead, conclude that d4T at C max concentrations in combination with CRP disturbs adipogenesis. By contrast, combination of AZT+CRP did not demonstrate an extra increase in the antiadipogenic properties of AZT, although we observed a further statistically non-significant reduction in FAS, ACC and aP2 expression. We propose that the already strong inhibitory effect of AZT on differentiation prevents further quantification of additional effects by CRP in our experimental system. The inhibitory effect on adipogenesis by combining d4T+CRP was accompanied by a decreased expression of adipogenic markers involved in lipid accumulation, such as FAS, ACC and aP2. As we were unable to detect combinatory effect on basic lipolysis and cell viability, it is tempting to speculate that the effect of the d4T+CRP combination is mainly exerted through inhibition of differentiation and lipid accumulation.
Adiponectin is an important adipokine exclusively secreted from adipose tissue [43] . Growing evidence suggests that adiponectin is an insulin-sensitizing hormone with direct anti-diabetic, anti-atherogenic and anti-inflammatory potentials [44, 45] . In vivo, a reciprocal association of adiponectin and CRP levels in both human plasma and adipose tissue has been reported [13] . Others have shown that short-term 24 h culture with 50 µg/ml CRP strongly inhibits adiponectin mRNA expression and secretion in fully differentiated adipocytes. The authors concluded that CRP restrains adiponectin gene expression in part through phosphatidylinositol (PI)-3 kinase pathway. This was because the LY294002 inhibitor of PI-3 kinase was able to partially reverse this effect [15] . In our experimental system, we analysed the effect of CRP during the process of differentiation requiring 9 days of incubation using CRP concentrations of 5 µg/ml. Our previous dose-response analyses had shown that a concentration of 5 µg/ml CRP did not significantly affect cell viability ( Figure 3B ) for the long-term incubation. This concentration correlates well to circulating serum levels in HIV patients [31] . The addition of CRP to the d4T and AZT incubations led to a moderate additional impairment of the already significantly affected adiponectin production by the NRTI, as the differences became highly significant under these conditions. These results collectively suggest that CRP modulates the antiadipogenic potential of d4T and might contribute to the lipoatrophic changes associated with d4T use in HIV-positive patients.
Insulin-sensitizing drugs, such as PPARγ agonists, have been shown to increase both adipocyte differentiation and adiponectin production in vitro as well as circulating adiponectin levels in vivo [19, 46] . As PPARγ agonists partially reverse the antiadipogenic effects of other proinflammatory factors, such as IL-6 [17] and TNF-α [47] , we decided to test whether Rosi would offset the antiadipogenic properties of the NRTI+CRP combinations in our experimental system. This, however, can not be convincingly concluded from our observations. Rosi seemed to exert only some beneficial effects on the secretion and expression of adiponectin in d4T and d4T+CRP cultures (Figure 4 ), presumably through a direct PPARγ-mediated effect on adiponectin transcription [48] . In addition, Yuan et al. [15] recently demonstrated that Rosi and CRP affect adiponectin gene expression via distinct pathways. On the basis of these observations and considering that neither d4T [23] nor CRP (data not shown) affect the process of clonal expansion, we propose that the observed joint inhibitory effect of d4T+CRP on differentiation is exerted after completion of clonal expansion. Taken together, our data support that CRP at levels circulating in patients with HIV infection promote the antiadipogenic potential of d4T. This cooperative effect could help to explain the in vivo observed variability in the development of peripheral fat wasting in HIV patients.
